Skip to main content
. 2023 Feb 27;2023(2):CD012922. doi: 10.1002/14651858.CD012922.pub2

Summary of findings 3. Methylxanthine derivatives versus inactive control for central sleep apnoea associated with heart failure in adults.

Theophylline 3.3 mg/kg (twice daily)compared to placebo for central sleep apnoea in adults
Patient or population: adults with central sleep apnoea associated with heart failure in adults
Setting: outpatients
Intervention: theophylline 3.3 mg/kg (twice daily)
Comparison: placebo
Outcomes Anticipated absolute effects* (95% CI) Relative effect (95% CI) № of participants
(studies) Certainty of the evidence
(GRADE)
Risk with placebo Risk with theophylline
cAHI
Follow‐up: mean 3 weeks (short‐term)
Mean cAHI was 26 events/hour MD 20.00 events/hour lower
(32.15 lower to 7.85 lower)
15
(1 RCT)
⊕⊝⊝⊝
Very lowa
Cardiovascular mortality Not reported
Serious adverse events Not reported
Quality of sleep Not reported
Quality of life Not reported
AHIFollow‐up: mean 3 weeks (short‐term) Mean AHI was 37 events/hour MD 19.00 events/hour lower
(30.27 lower to 7.73 lower) 15
(1 RCT) ⊕⊝⊝⊝
Very lowa
All‐cause mortality Not reported
*The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
AHI: apnoea‐hypopnoea index; cAHI: central apnoea‐hypopnoea index; CI: confidence interval; MD: mean difference; RCT: randomised controlled trial.
GRADE Working Group grades of evidenceHigh certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.
Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.

a Downgraded three levels due to serious study limitations (unclear risk of selection bias and reporting bias) and very serious imprecision (very small sample size and wide CI).